Indolent & mantle cell lymphoma - Clinical
LINKS TO ABSTRACTS:
Presentation ID p422-1
Presenter: Martin Dreyling, Munich, Germany
The study authors conclude that these data demonstrate the efficacy and acceptable safety of tisagenlecleucel in patients with r/r FL, including high-risk patients after multiple lines of prior therapy, and suggest that tisagenlecleucel may be a promising therapy for patients with r/r FL.
Presentation ID p422-2
Presenter: Pier Luigi Zinzani, Italy
The study authors conclude that copanlisib plus rituximab (C+R) demonstrated broad and superior efficacy versus rituximab plus placebo (P+R) in patients with relapsed iNHL. The safety profile of C+R was manageable and consistent with C and R as monotherapy. The authors finally conclude that copanlisib is the first PI3K inhibitor to be safely combined with R in relapsed iNHL, representing a potential new therapy option for relapsed iNHL across all subtypes.
Presentation ID p422-3
Presenter: Charles Herbaux, France
The study authors conclude that atezolizumab, obinutuzumab and venetoclax triplet appears to be well tolerated, with no unexpected toxicity brought by the combination, and the ORR at EOI seems to be comparable to other innovative regiments in this setting, with durable responses to date.
Presentation ID p422-4
(S213) OUTCOMES IN ZUMA-5 WITH AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WHO HAD THE HIGH-RISK FEATURE OF EARLY PROGRESSION AFTER FIRST CHEMOIMMUNOTHERAPY
Presenter: Caron Jacobson, Boston, United States
The study authors conclude that axicaptagene ciloleucel (Axi-cel) showed a high rate of durable responses in patients with POD24 iNHL, a population with high-risk disease. Efficacy results, as well as safety and pharmacological profiles, appeared largely comparable between groups, with the exception of progression-free survival rates.
Presentation ID p422-5
(S214) TOLERABILITY AND EFFICACY OF THE COMBINATION OF PI3KΔ INHIBITOR ZANDELISIB (ME-401) AND BTK INHIBITOR ZANUBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) B-CELL MALIGNANCIES: INITIAL RESULTS
Presenter: Jacob Soumerai, Boston, United States
The study authors conclude that the combination of zandelisib 60 mg on IS from Cycle 1 and zanubrutinib 80 mg bid is well tolerated and achieves a high ORR in R/R indolent B-cell malignancies.